SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL leukemia-trial readout is the dominant catalyst, with traders focused on whether GPS meets its survival endpoint. Bullish anticipation of a major revaluation and short squeeze is countered by concerns that the binary results could disappoint; sharp price swings have also fueled claims of short pressure and manipulation, which remain speculation.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported preliminary takeover discussions involving Silver Lake and Saudi Arabias PIF are driving attention, with traders debating whether a potential offer would undervalue Unity and whether a deal will happen. The debate is reinforced by strong Q3 results, first-ever GAAP profitability and rapid Vector advertising growth, which some investors cite as reasons Unity may be worth more independently.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Heavy trading and a sharp move have reignited speculation about a potential Big Pharma partnership or buyout, with Novo often named as a possible counterparty; no deal is confirmed. Traders are divided between seeing the activity as positioning around VK2735 and upcoming obesity-conference presentations and dismissing it as another rumor-driven pump amid a long wait for Phase 3 results.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is the dominant catalyst, with traders debating approval versus a possible rejection or delay. The debate centers on the drugs strong progression-free-survival results and favorable survival trend versus the FDAs stated need for statistically significant overall-survival evidence, driving uncertainty around the binary outcome.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure and uncertainty over Nvidias next CEO are driving debate, with traders weighing reports that the board approached Arm CEO Rene Haas against speculation Huang could return. Bulls view the selloff as a buying opportunity, while bears point to leadership uncertainty and unresolved China-related export scrutiny as risks.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly performance and raised outlook, attributed in the discussion to robust oral Wegovy demand, have fueled renewed interest in the shares. Bulls see the pill and international expansion as growth drivers, while skeptics point to Lillys competition, pricing pressure and execution concerns.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra shares are under pressure after the European regulator reaffirmed its negative opinion on arimoclomol (Miplyffa) for Niemann-Pick disease type C, with the European Commissions final decision still pending. Traders are divided on the selloff: some see the setback as largely expected and an overreaction given the existing U.S. business, while others fault management and view the lost European opportunity as significant.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmaxs better-than-expected Q3 results, with strong revenue growth and a return to profitability, are driving attention. Traders are reacting bullishly and discussing further momentum or a squeeze, while some caution that a one-time payment boosted reported revenue and question the quality of recurring earnings.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

A softer-than-expected monthly PPI reading is being weighed against accelerating year-over-year producer inflation, keeping traders focused on possible Fed rate hikes and elevated Treasury yields that pressure TLT. The community is split between expecting further bond weakness and viewing a recession or eventual rate cuts as a longer-term tailwind.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

Record Q3 results and raised full-year guidance have drawn attention, with traders pointing to international contract growth and demand for HawkEye 360s defense and signals-intelligence services. Sentiment is largely bullish around the strong share move and trading volume, while claims of institutional accumulation remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HELE Stock On Track For Best Day In Over 25 Years After Rejecting $37 Per Share Takeover Bid

Equity

Helen of Troy said its board determined the proposal from Empower Brands Holdings Group “substantially undervalues” the company.


CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop

DefenCath is CorMedix’s largest revenue driver in the dialysis setting, generating $258.8 million in net sales in 2025 and accounting for a majority of the company's reported full-year revenue of $311.7 million. 

Macy’s Raises Full Year Outlook After Strong Q2 — Says Inventories ‘Well-Positioned’ Heading Into Second Half Of 2026

Macy’s raised its fiscal 2026 outlook after comparable sales grew across all three nameplates, led by record second-quarter sales volume at Bloomingdale’s.

American Eagle Drops Big Ad Campaigns, Chases the Checkout 

American Eagle posted a quarterly profit beat that leaned on a $161 million tariff refund on Wednesday. 


LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value

Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights. 


QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upside

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity, the company said. 

QDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite Rally

QuidelOrtho is in talks to sell its point-of-care testing unit behind the rapid antigen tests for Covid and flu, Financial Times reported over the weekend. 


No Fed Rate Cut in 2026? ETFs to Gain 

Nomura joins Wall Street firms expecting no Fed rate cuts in 2026. These value, bank and cash-flow ETFs could benefit.

IMAX Stock Soars After Hours Following News Of Early-Stage Sale Process

According to a Wall Street Journal report, IMAX has begun gauging interest from possible buyers, including major entertainment companies. 


CARS Stock Rallies After-Hours On 11% Layoff, Increased Buyback Plans

The company said that the layoffs, in addition to process changes and vendor cost optimization, is expected to generate $25-30 million in recurring annualized operating cost savings in 2027. 


American Century ETF Trust - Avantis U.S. Small Cap Value ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company’s board argued that continuing to execute its multi-year strategic plan would create greater long-term value than accepting the “opportunistic” bid.</li><li>The board pointed to progress under CEO G. Scott Uzzell, who was appointed in September 2025.</li><li>Empower Brands, meanwhile, has framed its offer as providing immediate cash certainty at a premium to recent trading levels, with no financing contingency.</li></ul><p>Shares of Helen of Troy Limited (HELE) jumped as much as 27% on Wednesday after the consumer products company confirmed it had unanimously rejected an unsolicited $37-per-share all-cash takeover proposal.</p><p>The stock climbed from a prior close near $29.54 to trade around $37, putting it on track for its best day since July 2001, if the gains hold.</p><p>Helen of Troy, a global consumer products company that owns or licenses brands including OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools, Drybar, Curlsmith, Revlon and Olive &amp; June, said its board determined the proposal from Empower Brands Holdings Group “substantially undervalues” the company. Empower Brands is owned by Spectrum Brands and Oaktree Capital Management. The board argued that continuing to execute its multi-year strategic plan would create greater long-term value than accepting the “opportunistic” bid.</p><h2 class="st-heading-2">Helen’s Rationale For Rejecting Bid</h2><p>Helen of Troy said the board, after reviewing the proposal with financial and legal advisers, concluded it was not in the best interests of the company or its shareholders. The firm noted that Empower Brands first submitted a $34-per-share proposal in August 2026, which was rejected, then raised the offer to $37 in October. The company said Empower Brands declined to enter a standard non-disclosure agreement that would have allowed further diligence, which Helen of Troy characterized as underscoring the opportunistic nature of the approach. The proposal came amid a period of stock-price dislocation linked in part to tariff-related disruption, the company added.</p><p>The board pointed to progress under CEO G. Scott Uzzell, who was appointed in September 2025. Helen of Troy recently reported strong second-quarter fiscal 2027 results, raised guidance, and is reinvesting $66.5 million to $70.5 million of tariff refunds into the business, it noted. The company outlined a three-phase roadmap in April that targets low-to-mid-single-digit sales growth, high-single-digit adjusted core profit growth, mid-to-high-teens adjusted earnings per share growth, and free cash flow conversion approaching 75% by year five of the plan.</p><p>“The Board remains open to opportunities that are in the best interest of Helen of Troy and its shareholders and will appropriately consider opportunities consistent with its fiduciary duties,” the company said.</p><h2 class="st-heading-2">Empower’s Rationale</h2><p>Empower Brands, meanwhile, has framed its offer as providing immediate cash certainty at a premium to recent trading levels, with no financing contingency.</p><p>“We believe our all-cash proposal offers Helen of Troy’s shareholders compelling and certain value at an attractive premium. As Helen of Troy is currently comprised, it does not have the scale or the financial ability to acquire or achieve the scale to compete in a landscape that we know well,” Spectrum Brands CEO David Maura said. The firm also highlighted the near 87% decline in HELE's share price over the past five years, the company's repeated earnings disappointments, and its changing leadership, with three CEOs in the past three years.</p><h2 class="st-heading-2">How Did HELE Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$HELE" data-symbol-id="HELE" href="https://stocktwits.com/symbol/HELE" target="_blank">HELE stock</a> jumped from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume jumped from 'extremely low' to 'high' levels.</p><p>A Stocktwits user noted that the shares are undervalued and have significant potential upside.</p><p><stembedurl>https://stocktwits.com/MuneeMakr/message/668122836</stembedurl></p><p>HELE stock has gained 73% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vst-ceg-stocks-drop-as-election-outcome-hits-merchant-power-generators/cNGLkduR93x">VST, CEG Stocks Drop As Election Outcome Hits Merchant Power Generators</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Helen of Troy Limited logo is seen displayed on a smartphone screen

Helen of Troy said its board determined the proposal from Empower Brands Holdings Group “substantially undervalues” the company.

Helen of Troy Ltd

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Nice to see $AVUV up a bit today. It will recover. Such a great ETF if you can hold onto it.

Feed

News

Sentiment

Fundamentals

Info

AVUV American Century ETF Trust - Avantis U.S. Small Cap Value ETF

Fundamentals

Latest AVUV News